tacrine has been researched along with propylene glycol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jogani, VV; Mishra, AK; Mishra, P; Misra, AR; Shah, PJ | 1 |
| Bernkop-Schnürch, A; Csóka, I; Ismail, R; Laffleur, F; Phan, TNQ | 1 |
2 other study(ies) available for tacrine and propylene glycol
| Article | Year |
|---|---|
Nose-to-brain delivery of tacrine.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Biological Availability; Biological Transport; Blood-Brain Barrier; Brain; Cholinesterase Inhibitors; Drug Delivery Systems; Drug Stability; Injections, Intravenous; Mice; Mice, Inbred BALB C; Propylene Glycol; Rabbits; Radionuclide Imaging; Random Allocation; Tacrine; Technetium; Time Factors; Tissue Distribution | 2007 |
Hydrophobic ion pairing of a GLP-1 analogue for incorporating into lipid nanocarriers designed for oral delivery.
Topics: Administration, Oral; Animals; Biological Availability; Caprylates; Dioctyl Sulfosuccinic Acid; Drug Carriers; Drug Delivery Systems; Exenatide; Glucagon-Like Peptide 1; Glycerides; Humans; Hydrophobic and Hydrophilic Interactions; Lipids; Male; Nanoparticles; Polyethylene Glycols; Propylene Glycol; Rats; Rats, Sprague-Dawley; Solubility; Surface-Active Agents; Tacrine | 2020 |